There is no convincing evidence that glitazones offer clinical benefit over metformin or sulphonylureas when used as monotherapy in type 2 diabetes,the Drug and Therapeutics Bulletin has concluded(2008;46:25).Glitazones should be reserved,the DTB says,for use in combination with a sulphony-lurea for patients unsuitable for treatment with metformin or in combination with metformin for patients unsuitable for treatment with a sulphonylurea.
展开▼
